# EDGAR Filing Document

**Accession Number:** 0001937737
**File Stem:** 0001213900-26-001475
**Filing Date:** 2026-1
**Character Count:** 7190
**Document Hash:** 62d1f372ba7f8fa717b86c056b864aef
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-001475.hdr.sgml**: 20260106

**ACCESSION NUMBER**: 0001213900-26-001475

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260105

**FILED AS OF DATE**: 20260106

**DATE AS OF CHANGE**: 20260105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Moolec Science SA
- **CENTRAL INDEX KEY:** 0001937737
- **STANDARD INDUSTRIAL CLASSIFICATION:** TEXTILE MILL PRODUCTS [2200]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41586
- **FILM NUMBER:** 26509149

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 89 NEXUS WAY, CAMANA BAY
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-9009
- **BUSINESS PHONE:** 352 26 49 65 65

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 89 NEXUS WAY, CAMANA BAY
- **CITY:** GRAND CAYMAN
- **PROVINCE COUNTRY:** E9
- **ZIP:** KY1-9009

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of the** 

**Securities Exchange Act of 1934**

**For the month of January 2026**

**Commission File Number: 001-41586**

**MOOLEC SCIENCE SA**

(Exact name of Registrant as Specified in Its Charter)

**89 Nexus Way, Camana Bay**

**Grand Cayman KY1-9009**

**Cayman Islands**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**EXPLANATORY NOTE**

The information contained in this Form 6-K and any exhibits hereto shall be deemed to be incorporated by reference into the Company's registration statement on [Form S-8](https://www.sec.gov/Archives/edgar/data/1937737/000121390024080686/ea0214775-s8_moolec.htm) (Registration No. 333-282263).

**EXHIBIT INDEX**

The following exhibits are filed as part of this Form 6-K:

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [Press Release](ea027194901ex99-1_moolec.htm)<u> </u> |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Moolec Science SA | Moolec Science SA |
|  | (registrant) | (registrant) |
| Date: January 5, 2026 | By: | /s/ Alejandro Antalich |
|  | Name: | Alejandro Antalich |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Moolec Science Announces Effectiveness of Share Consolidation**

Moolec Science SA ("Moolec" or the "Company") today announced that, in accordance with the resolutions passed at the extraordinary general meeting of shareholders held on December 16, 2025, and the resolutions adopted by the Company's board of directors on December 19, 2025, the Company has consummated, effective as of January 5, 2026, the previously announced share consolidation at a ratio of 15-for-1, so that all shareholders holding every 15 ordinary shares of par value of US$0.10 each will hold 1 ordinary share of par value US$1.50 each (the "Share Consolidation").

As a result, every 15 ordinary shares of the Company, par value US$0.10 per share each (with par value to be amended from time to time, the "Shares"), issued and outstanding immediately prior to the Share Consolidation, were automatically consolidated into 1 validly issued, par value US$1.50 each, fully paid and non-assessable Share, without any action required by any shareholder.

The Share Consolidation became effective on January 5, 2025, at 8:00 a.m. Eastern Time (the "Effective Date") and is reflected in the market as of the start of trading today on a consolidation-adjusted basis.

The Company's ordinary shares continue to trade on The Nasdaq Stock Market under the symbol "MLEC" under a new CUSIP number G6223S 125. The Company's publicly traded warrants continue to trade under the symbol "MLECW" under the same CUSIP number G6223S 117.

As a result of the Shre Consolidation, the number of issued and outstanding Shares was reduced from 10,891,761 to 726,118 Shares. The Share Consolidation does not otherwise affect the Company's business or operations.

Registered shareholders are not required to take any action to receive shares in connection with the Share Consolidation. Shareholders who hold their shares through a brokerage firm, bank, dealer, custodian or other nominee will have their positions automatically adjusted to reflect the Share Consolidation, subject to their broker's particular processes, and will not be required to take any action in connection therewith.

**Forward-looking Statements**

This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to the Company's plan to regain compliance under the Nasdaq rules, performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.